SOPRANO

A trial of stereotactic body radiotherapy (SBRT) with niraparib in people with ovarian cancer.

Treatment Modality: .

Status: Enrolling participants

What is the study about?

SOPRANO investigates targeted radiotherapy either on its own or followed by a drug called niraparib for certain types of advanced ovarian cancer.

People with ovarian cancers are often treated with PARP inhibitors, a type of drug which works by blocking the ability of cancer cells to repair themselves. These cancer cells become too damaged to survive and they die.

Despite treatment with PARP inhibitors, cancer can grow or spread in small areas around the body. These small areas of cancer can be treated with stereotactic radiotherapy (SBRT). SBRT uses lots of radiation beams to target the cancer, reducing radiation to surrounding areas of the body. This allows very small areas of cancer to be precisely treated. SBRT may work even better when followed by another course of a PARP inhibitor.

SOPRANO will investigate whether giving SBRT on its own or followed by the PARP inhibitor niraparib will prevent certain types of advanced ovarian cancer from getting worse.

Who is included in the study?

SOPRANO includes people with certain types of advanced ovarian cancer, which has grown in small areas throughout the body during or after treatment with a PARP inhibitor. People with the following types of cancer may join the trial:

Epithelial ovarian cancer
Primary peritoneal cancer
Fallopian tube cancer

Forty-two people will be included from up to six NHS hospitals across the UK.

What are the study treatments?

When people join the SOPRANO trial, they will be put into one of two groups:

SBRT followed by niraparib
SBRT alone

SBRT will be given to all the small areas of cancer growth during 3 to 8 hospital visits over 5 to 19 days, depending on the areas being treated. After SBRT finishes, people in the SBRT followed by niraparib group will take niraparib tablets once a day.

Participants have regular check ups during and after their treatment and we collect information about how they are getting on until the study is completed.

Further information for participants

Patient information sheet

Lay Summary

Further information for healthcare professionals

Trial Summary

Trial Schema

View a plain English summary from Cancer Research UK

SOPRANO QR code

Contact details and regulatory information

Chief Investigator: Professor Susana Banerjee, The Royal Marsden NHS Foundation Trust

SBRT Lead: Dr Alexandra Taylor, The Royal Marsden NHS Foundation Trust

ICR-CTSU Scientific Lead: Professor Judith Bliss

Trial management contact: [email protected]

Sponsor: The Institute of Cancer Research

Funding: GlaxoSmithKline (GSK)